The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Open accessAbstract
BACKGROUND: Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. METHODS: We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months, at a dose of 60 mg, administered subcutaneously every 6 months. The coprimary end points were the cumulative incidences of new vertebral fractures at 12 months and 24 months. Secondary end points included clinical (a composite of nonvertebral and symptomatic vertebral) and nonvertebral fractures. RESULTS: At 12 months, new vertebral fractures had occurred in 16 of 3321 patients (0.5%) in the romosozumab group, as compared with 59 of 3322 (1.8%) in the placebo group (representing a 73% lower risk with romosozumab; P<0.001). Clinical fractures had occurred in 58 of 3589 patients (1.6%) in the romosozumab group, as compared with 90 of 3591 (2.5%) in the placebo group (a 36% lower risk with romosozumab; P=0.008). Nonvertebral fractures had occurred in 56 of 3589 patients (1.6%) in the romosozumab group and in 75 of 3591 (2.1%) in the placebo group (P=0.10). At 24 months, the rates of vertebral fractures were significantly lower in the romosozumab group than in the placebo group after each group made the transition to denosumab (0.6% [21 of 3325 patients] in the romosozumab group vs. 2.5% [84 of 3327] in the placebo group, a 75% lower risk with romosozumab; P<0.001). Adverse events, including instances of hyperostosis, cardiovascular events, osteoarthritis, and cancer, appeared to be balanced between the groups. One atypical femoral fracture and two cases of osteonecrosis of the jaw were observed in the romosozumab group. CONCLUSIONS: In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months. The lower risk of clinical fracture that was seen with romosozumab was evident at 1 year. (Funded by Amgen and UCB Pharma; FRAME ClinicalTrials.gov number, NCT01575834 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It achieves this by upregulating the Wnt pathway while also acting as an enhancer of RANKL synthesis, thereby downregulating this latter pathway [83,84,85].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it uniquely exhibits the ability to stimulate bone formation while simultaneously reducing bone resorption.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [83]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Romosozumab is a newly approved monoclonal antibody targeting sclerostin.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A systematic review of hip fracture incidence and probability of fracture worldwide
Kanis, J. A., Odén, A., McCloskey, E. V., Johansson, H., Wahl, D. A., Cooper, C. C., & on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) · Osteoporosis International · doi:10.1007/s00198-012-1964-3 · Cited by 1,382
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citationIncreased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Estimating Hip Fracture Morbidity, Mortality and Costs
Braithwaite, R. S., Col, N. F., & Wong, J. B. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51110.x · Cited by 915
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,001
Inage, K., Orita, S., Eguchi, Y., Shiga, Y., Koda, M., Aoki, Y., Kotani, T., Akazawa, T., Furuya, T., Nakamura, J., et al. (2021) · Yonsei Medical Journal · doi:10.3349/ymj.2021.62.9.829 · Cited by 8
Romosozumab used to treat a patient with cystic fibrosis-related osteoporosis
Crow, H., Graves, L., & Anabtawi, A. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.04.018 · Cited by 8
Inose, H., Kato, T., Tomizawa, S., Ariga, A., Motoyoshi, T., Fukushima, K., Takahashi, K., Yoshii, T., & Okawa, A. (2022) · Bone Reports · doi:10.1016/j.bonr.2022.101635 · Cited by 9
The WNT/β-catenin system in chronic kidney disease-mineral bone disorder syndrome
Zhang, L., Adu, I. K., Zhang, H., & Wang, J. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03569-2 · Cited by 9
Pandey, P., Sharma, A., & Gogia, A. (2023) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2023.100959 · Cited by 9
Nakamura, K., Koide, M., Kobayashi, Y., Yamashita, T., Matsushita, M., Yasuda, H., Ishihara, Y., Yoshinari, N., & Udagawa, N. (2023) · Journal of Periodontal Research · doi:10.1111/jre.13134 · Cited by 8
Improving Kidney Disease Care: One Giant Leap for Nephrology
Provenzano, M., Hu, L., Tringali, E., Senatore, M., Talarico, R., Dio, M. D., Ruotolo, C., Manna, G. L., Garofalo, C., & Zaza, G. (2024) · Biomedicines · doi:10.3390/biomedicines12040828 · Cited by 8
Yu, S., Huang, W., Zhang, H., Guo, Y., Zhang, B., Zhang, G., & Lei, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116414 · Cited by 9
Ayers, C. K., Ward, R., & Kansagara, D. L. (2024) · Annals of Internal Medicine · doi:10.7326/l24-0118 · Cited by 8
Aterosclerosis, calcificación vascular y osteoporosis
Valero, C., & Macías, J. G. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2024.07.004 · Cited by 8
Role of Sclerostin in Cardiovascular System
Zhang, N., Wang, L., Li, X., Yang, X., Tao, X., Jiang, H., Yu, Y., Liu, J., Yu, S., Ma, Y., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104552 · Cited by 10
Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders
Trajanoska, K., & Rivadeneira, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.556610 · Cited by 8
Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody
Morrell, A. E., Robinson, S. T., Ke, H. Z., Holdsworth, G., & Guo, X. E. (2021) · Bone · doi:10.1016/j.bone.2021.115967 · Cited by 8
Seltene Erkrankungen des Mittelohres und der lateralen Schädelbasis
Weiss, N. M. (2021) · Laryngo-Rhino-Otologie · doi:10.1055/a-1347-4171 · Cited by 8
Wang, W., Tseng, W., Zhao, H., Azar, T., Pei, S., Jiang, X., Dyment, N. A., & Liu, X. S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121015 · Cited by 8
Dai, Z., Fang, P., Yan, X., Zhu, R., Feng, Q., Yan, Q., Yang, L., Fan, X., Xie, Y., Zhuang, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.770073 · Cited by 9
Antitumor Effect of Sclerostin against Osteosarcoma
Ideta, H., Yoshida, K., Okamoto, M., Sasaki, J., Kito, M., Aoki, K., Yoshimura, Y., Suzuki, S.-I., Tanaka, A., Takazawa, A., et al. (2021) · Cancers · doi:10.3390/cancers13236015 · Cited by 10
The Impact of COVID-19 in Bone Metabolism: Basic and Clinical Aspects
Tsourdi, E. A., Hofbauer, L. C., & Rauner, M. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1825-9641 · Cited by 8
Self-citationMetabolism and Endocrine Disorders: What Wnt Wrong?
Franco, C. N., Noe, M. M., & Albrecht, L. V. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.887037 · Cited by 8
DeSapri, K. T., & Batur, P. (2019) · Journal of Women s Health · doi:10.1089/jwh.2019.8195 · Cited by 8
Diagnose und Therapie der Osteoporose bei Patienten mit chronischer Niereninsuffizienz
Cejka, D., Wakolbinger, R., Zitt, E., Fahrleitner‐Pammer, A., Amrein, K., Dimai, H. P., & Muschitz, C. (2022) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-022-00989-0 · Cited by 8
Got WNTS? Insight into bone health from a WNT perspective
Craig, S. E. L., Michalski, M. N., & Williams, B. O. (2023) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2023.01.004 · Cited by 10
Trends in Management of Osteoporosis Following Primary Vertebral Compression Fracture
Malacon, K. E., Beach, I. R., Touponse, G. C., Rangwalla, T., Lee, J. S., & Zygourakis, C. C. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad085 · Cited by 8
Overview of bone microstructure, and treatment of bone fragility in chronic kidney disease
Seeman, E. (2017) · Nephrology · doi:10.1111/nep.13024 · Cited by 7
Abrahamsen, B., Ernst, M., Smith, C., Nybo, M., Rubin, K. H., Prieto‐Alhambra, D., & Hermann, A. P. (2020) · Bone · doi:10.1016/j.bone.2020.115371 · Cited by 8
Melatonin having Therapeutic Bone Regenerating Capacity in Biomaterials
Huang, J., Li, Y., & He, C. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210709145347 · Cited by 8
Current Treatment of Osteoporosis
Nallasivan, S. (2018) · Indian Journal of Rheumatology · doi:10.4103/injr.injr_74_18 · Cited by 9
Building Better Bones with Biologics — A New Approach to Osteoporosis?
Rosen, C. J., & Ingelfinger, J. R. (2016) · New England Journal of Medicine · doi:10.1056/nejme1611863 · Cited by 8
Cardiovascular Safety and Romosozumab—The Plot Thickens
Farr, J. N. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae313 · Cited by 8
The Potential of Indole Alkaloids in Bone Health and Osteoporosis Management
Caruso, A., Caira, V., El‐Kashef, H., & Saturnino, C. (2024) · Applied Sciences · doi:10.3390/app14188124 · Cited by 7
Tan, C., Cong, S., Xie, Y., & Zhi, Y.-J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083650 · Cited by 8
Teraguchi, M., Kitayama, Y., Yamada, Y., Nakamoto, Z., Yamaoka, Y., & Yamada, H. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf096 · Cited by 7
Bustamante-Gomez, C., Fu, Q., Goellner, J. J., Thostenson, J. D., Reyes-Pardo, H., & O’Brien, C. A. (2025) · Bone · doi:10.1016/j.bone.2025.117567 · Cited by 7
Adami, G., Bartezaghi, M., Montanari, F., Piccinelli, A., Pollastri, F., Mastropaolo, F., Giorgio, F., Benini, C., Fassio, A., Rossini, M., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07722-8 · Cited by 7
Abdalbary, M., Amin, A. M., Elaraby, A. R., & Hassan, A. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07707-7 · Cited by 8
Gielen, E., Amini, N., Coppens, D., Dejaeger, M., Dupont, J., de Vlam, K., Rossini, M., Viapiana, O., Laurent, M. R., & Adami, G. (2025) · Bone · doi:10.1016/j.bone.2025.117701 · Cited by 7
Ena, G., & Soyfoo, M. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010102 · Cited by 8
Adynamic bone disease: Revisited
Sharma, S., & Gupta, A. (2021) · Nefrología · doi:10.1016/j.nefro.2020.11.012 · Cited by 12
An Overview of Osteoporosis Management
Jiang, N. S., Newton, B., & Jiang, X. (2021) · OBM Geriatrics · doi:10.21926/obm.geriatr.2104181 · Cited by 7
Romosozumab for the treatment of postmenopausal women at high risk of fracture
Geusens, P., Appelman‐Dijkstra, N. M., Lems, W. F., & van den Bergh, J. P. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2152320 · Cited by 7
Chankamngoen, W., Krungchanuchat, S., Thongbunchoo, J., Sirinonthanawech, N., Teerapornpuntakit, J., Panupinthu, N., & Charoenphandhu, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-48436-3 · Cited by 8
Kimura, S., Sunouchi, T., Watanabe, S., Hoshino, Y., Hidaka, N., Kato, H., Takeda, S., Nangaku, M., Makita, N., Azuma, K., et al. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07168-4 · Cited by 7
Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019–2021
Soen, S., Wang, A. Y., Hamaya, E., Chien, H., & Lin, T. (2024) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-024-01530-6 · Cited by 7
Inose, H., Takahashi, S., Teraguchi, M., Kato, T., Yamada, K., Yasuda, H., Terakawa, M., Minetama, M., Tomori, M., Nakagawa, Y., et al. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae137 · Cited by 7
Li, H., Fu, Z., Tao, A., Wu, T., Zhan, X., Tang, H., Cui, X., Ma, Z., Li, C., Jiang, J., et al. (2024) · Bone · doi:10.1016/j.bone.2024.117340 · Cited by 7
First‐line treatment of osteoporosis with osteoanabolic therapy: a new opportunity
Aleksova, J., & Ebeling, P. R. (2025) · Internal Medicine Journal · doi:10.1111/imj.70061 · Cited by 7
Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 cases
Everts‐Graber, J., Ferrari, S., Popp, A. W., Hars, M., Wenger, M., Oser, S., Studer, U., Steiner, C., Ziswiler, H., Schmid, G., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01598-1 · Cited by 7
Self-citationCellular Contributors to Bone Homeostasis
Rauner, M., Jähn, K., Hemmatian, H., Colditz, J., & Goettsch, C. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-46725-8_16 · Cited by 6
New therapeutic options for bone diseases
Kocijan, R., Haschka, J., Feurstein, J., & Zwerina, J. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-020-00810-w · Cited by 7
The role of bone anabolic drugs in the management of periodontitis: a scoping review
Cecoro, G., Paoletta, M., Annunziata, M., Laino, L., Nastri, L., Gimigliano, F., Liguori, S., Toro, G., Moretti, A., Guida, L., et al. (2021) · European Cells and Materials · doi:10.22203/ecm.v041a20 · Cited by 7
A bibliometric analysis of Wnt signaling pathway: from the top-100 cited articles to emerging trends
Xu, J., Tang, N., Zhang, L., Tan, C., Su, Y., George, D. M., He, G., & Huang, T. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-174 · Cited by 7
Chandra, A., Rosenzweig, A. B., & Pignolo, R. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-72228-3_1 · Cited by 6
Lee, C., Fu, S., Chen, H., Lin, J., Hsu, C., Lin, S.-C., Hwang, J., Yang, R., Wu, C., & Wang, C. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.05.022 · Cited by 7
Peng, Y., Langermann, S., Kothari, P., Liu, L. L., Zhao, W., Hu, Y., Chen, Z., Perini, M. M. D. L., Li, J., Cao, J., et al. (2023) · JBMR Plus · doi:10.1002/jbm4.10825 · Cited by 7
Self-citationRomosozumab — getting there but not quite yet
Papapoulos, S. E. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.179 · Cited by 7
Simfia, I., Schiavi, J., & McNamara, L. M. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112264 · Cited by 7
McDonald, G. L. K., Wang, M., Hammond, C. L., & Bergen, D. J. M. (2021) · Biomolecules · doi:10.3390/biom11020277 · Cited by 7
Decreased Serum Wnt Antagonist Levels in Patients With Active Acromegaly
Chen, H., Huang, H., Wang, Y., Zhang, Y., Liu, M., Lou, Y., Zhang, Z., Zhu, D., & Li, P. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.01.011 · Cited by 8
Serum Sclerostin Level Is Negatively Associated with Bone Mineral Density in Hemodialysis Patients
Lu, J.-W., Syu, R., Wang, C., Hsu, B., & Tsai, J. (2022) · Medicina · doi:10.3390/medicina58030385 · Cited by 7
Mechanical Load, Sex Hormones, and Bone Modeling
Windahl, S. H., & Lerner, U. H. (2021) · Wiley eBooks · doi:10.1002/9781119608912.ch7 · Cited by 7
The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
Fassio, A., Gatti, D., Biffi, A., Ronco, R., Porcu, G., Adami, G., Alvaro, R., Bogini, R., Caputi, A. P., Cianferotti, L., et al. (2024) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x241234584 · Cited by 7
Inokuchi, S., & Shimamoto, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1411285 · Cited by 6
Extending the Therapeutic Potential: Romosozumab in Osteoporosis Management
Liu, L. Q., Clifton-Bligh, R. J., Girgis, C. M., & Gild, M. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae160 · Cited by 7
Du, Y., Gao, X., Chen, J., Chen, X., Liu, H., He, W.-G., Liu, L., Jiang, Y., He, B., Deng, Z., et al. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.10.004 · Cited by 6
Cuadra-Llopart, L., Sierra, T. P., Sáez-López, P., Etxebarría-Foronda, Í., & Rey, J. R. C. (2024) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2024.101582 · Cited by 6
Wei, L., Chiu, C.-M., Kok, S., Chang, H., Cheng, S., Lin, H., Chiu, W., & Lee, J. (2025) · Journal of Dental Sciences · doi:10.1016/j.jds.2025.02.002 · Cited by 6
Tominaga, A., Wada, K., Kato, Y., & Okazaki, K. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf049 · Cited by 6
Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study
Diz-Lopes, M., Pollastri, F., Mastropaolo, F., Somma, R., Tugnolli, M., Pasetto, E., Benini, C., Messina, V., Gatti, D., Viapiana, O., et al. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf144 · Cited by 7
Novel therapies in osteoporosis – Clinical update – 2025
Inderjeeth, C. A., & Inderjeeth, D. C. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102100 · Cited by 7
Low Vitamin K Status, High Sclerostin and Mortality Risk of Stable Coronary Heart Disease Patients
Mayer, O., Bruthans, J., Seidlerová, J., Gelžinský, J., Kučera, R., Karnosová, P., Mateřánková, M., Rychecká, M., Wohlfahrt, P., Cífková, R., et al. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0168 · Cited by 6
Huang, J., Li, Y., Zhu, S., Wang, L., Pei, H., Wang, X., Bao, T., Jiang, Z., Yang, L., & He, C. (2023) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1155/2023/8857436 · Cited by 6
Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa
Fujimoto, K., Maki, N., Hashiba, D., Maeyama, T., Nakagawa, R., Arai, H., & Ohtori, S. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.10.001 · Cited by 6
Pol, V., Kaur, T., Bhardwaj, A., Sapra, L., Yadav, S., & Srivastava, R. K. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003712 · Cited by 6
Wang, T., Xiong, K., He, Y., Feng, B., Guo, L., Gu, J., Zhang, M., Wang, H., & Wu, X. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00113.2024 · Cited by 7
Kumar, S., Beck, B. R., Nery, L., Byth, K., Elhindi, J., Wood, C., Fuller, O. K., Clifton-Bligh, R. J., & Girgis, C. M. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086708 · Cited by 9
Responders and non-responders to romosozumab treatment
Tominaga, A., Wada, K., Kato, Y., & Okazaki, K. (2024) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-024-01570-y · Cited by 6
Lee, S., Hong, N., Cho, S., Shin, S., & Rhee, Y. (2025) · Osteoporosis International · doi:10.1007/s00198-024-07336-6 · Cited by 6
Martinez, J. P. D., Maraumont, T. A.-D., Sánchez, E. N., Cordero, L. M. C., & Yeh, E. J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0299673 · Cited by 7
Mun, H. W., Lee, J. J., Shin, H., Kim, T.-H., Kim, S. W., & Oh, J. K. (2025) · Neurospine · doi:10.14245/ns.2449228.614 · Cited by 6
Nanomaterials‐Based Drug Delivery Systems for Therapeutic Applications in Osteoporosis
Shi, D., Li, Y., Tian, M., Xue, M., Wang, J., & An, H. (2025) · Advanced Biology · doi:10.1002/adbi.202400721 · Cited by 7
A History of Pivotal Advances in Clinical Research into Bone and Mineral Diseases
Cummings, S. R., & Eastell, R. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3353 · Cited by 6
Pharmacological treatment of osteoporosis
Chun, S. (2019) · Journal of Korean Medical Association · doi:10.5124/jkma.2019.62.10.542 · Cited by 6
Aspects of intercellular communication in bone and implications in therapy
Martin, T. J. (2021) · Bone · doi:10.1016/j.bone.2021.116148 · Cited by 6
Henríquez, M. S., & Romero, M. G. D. T. (2021) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2021000200006 · Cited by 6
Estradiol and RSPO3 regulate vertebral trabecular bone mass independent of each other
Nilsson, K. H., Wu, J., Gustafsson, K. L., Shahawy, M. E., Koskela, A., Tuukkanen, J., Tuckermann, J. P., Henning, P., Lerner, U. H., Ohlsson, C., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00383.2021 · Cited by 7
A retrospective review of the community medicine needs from osteoporosis services in Canada
Kline, G. A., Symonds, C. J., & Billington, E. O. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01000-y · Cited by 6
Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
Khanjee, N., & Maalouf, N. M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac159 · Cited by 6
Kitaura, Y., Nakamura, U., Awada, C., Yamaguchi, M., Kim, M., Ikeda, Y., Matsuo, Y., Moriishi, T., Sawase, T., Chung, U., et al. (2022) · Regenerative Therapy · doi:10.1016/j.reth.2022.11.002 · Cited by 7
Dai, Z., Zhu, R., Sheng, Z., Qin, G., Luo, X., Qin, Q., Song, C., Li, L., Jin, P., Yang, G., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168757 · Cited by 6
An Update on Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis
Bennett, B., Tahir, H., Solanki, K., & Ali, N. (2023) · EMJ Rheumatology · doi:10.33590/emjrheumatol/10300262 · Cited by 6
Okuyama, K., Inage, K., Kim, G., Mukaihata, T., Tajiri, I., Shiga, Y., Inoue, M., Eguchi, Y., Suzuki, M., Otagiri, T., et al. (2024) · Journal of Orthopaedic Research® · doi:10.1002/jor.25834 · Cited by 6
Morley, J. E. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.11.001 · Cited by 6
Galli, C., Colangelo, M. T., Pedrazzi, G., & Guizzardi, S. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00554-9 · Cited by 6
Einfluss spezifischer Osteoporosemedikamente auf die Frakturheilung
Hesse, E., Neuerburg, C., Kammerlander, C., Stumpf, U. C., Stange, R., & Böcker, W. (2019) · Der Unfallchirurg · doi:10.1007/s00113-019-0669-x · Cited by 27
LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells
Heo, S., Choi, Y., Jeong, Y. K., Ju, L. J., Yu, H.-M., Kim, D. K., Seo, H. J., Lee, Y. J., Cheon, J., Koh, S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247368 · Cited by 6
Differentially expressed genes and miRNAs in female osteoporosis patients
Zhou, H., Jiang, J., Chen, X., & Zhang, Z. (2022) · Medicine · doi:10.1097/md.0000000000029856 · Cited by 6
Long, Z., Wu, J., Xiang, W., Yuan, M.-X., Wu, Y., Li, J., Yu, G., & Yang, T. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/7017610 · Cited by 6
Wong, S. C., Straub, V. W., Ward, L. M., Quinlivan, R. C. M., Adachi, J., Ahmed, S. F., Anderton, M., Broggi, F., Crabtree, N. J., de Groot, I. J. M., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.01.002 · Cited by 6
Self-citationEvaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis
Di, Y., Wasan, E. K., Cawthray, J. F., Syeda, J., Ali, M., Cooper, D. M. L., Al-Dissi, A. N., Ashjaee, N., Cheng, W.-B., Johnston, J. D., et al. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.100753 · Cited by 6
Orthogeriatrics and Hip Fractures
Sanford, A. M., Morley, J. E., & McKee, A. M. (2018) · The journal of nutrition health & aging · doi:10.1007/s12603-018-1007-7 · Cited by 6
Metadata
- Authors
- Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., Zerbini, C. A. F., Milmont, C. E., Chen, L., Maddox, J., Meisner, P. D., Libanati, C., & Grauer, A.
- Affiliations
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-10-20
- Volume
- 375
- Issue
- 16
- Pages
- 1532-1543
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2520995084
- Cited by
- 1,805
- References
- 24
- Citations by year
- 2026: 225 · 2025: 223 · 2024: 219 · 2023: 168 · 2022: 194 · 2021: 192 · 2020: 182 · 2019: 141 · 2018: 131 · 2017: 110 · 2016: 16
- FWCI
- 161.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, osteoporosis, postmenopausal women, vertebral fractures, non-vertebral fractures, denosumab, bone formation, bone resorption, fracture risk reduction, monoclonal antibodies, adverse events, hyperostosis, cardiovascular events, osteoarthritis, cancer risk, RANKL
- MeSH terms
- Denosumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Bone Remodeling, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
